Tyme Technologies (TYME) Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. USO
2. MRVL
3. SPY
4. NVDA
5. GOOGL
6. CHRW
7. OPCH
8. BBIO
9. APLD
10. AMD

Go back to Tyme Technologies (TYME) Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections

TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections

February 3, 2021 8:00 AM EST

BEDMINSTER, N.J.--(BUSINESS WIRE)-- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Companys metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19.

Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and... More